[The pharmacodynamics of the new anti-arrhythmia preparation bonnecor in patients with extrasystoles].

Abstract

The pharmacodynamics, antiarrhythmic activity and tolerance of bonnecor were studied in 25 patients with acute myocardial infarction (AMI) and 23 patients with chronic ischemic heart disease (IHD) complicated by cardiac rhythm disorders in the form of extrasystoles. Extrasystoles were revealed in 92% of AMI patients at a single administration of bonnecor and in 82.5% of IHD patients at long-term oral administration of the drug. Bonnecor exerted no influence on arterial blood pressure and heart rate, did not change the parameters of the intracardiac hemodynamics. Bonnecor is well tolerated by patients, its main side effect is the prolongation of PQ interval of the ECG.

• Authors: L I Ol'binskaia, M A Rybakov, Zh M Sizova
• Journal: Farmakologiia i toksikologiia (Farmakol Toksikol) 1990 May-Jun Vol. 53 Issue 3 Pg. 63-4 ISSN: 0014-8318 [Print] Russia (Federation)
• Vernacular Title: Farmakodinamika novogo antiaritmicheskogo preparata bonnekora u bol'nykh s ékstrasistoliiami.
• PMID: 1696910 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Dibenzazepines
• tiracizine

Topics

• Anti-Arrhythmia Agents (pharmacology, therapeutic use)
• Cardiac Complexes, Premature (drug therapy, etiology, physiopathology)
• Coronary Disease (complications, drug therapy, physiopathology)
• Dibenzazepines (pharmacology, therapeutic use)
• Drug Evaluation
• Drug Tolerance
• Electrocardiography (drug effects)
• Female
• Heart (drug effects, physiopathology)
• Hemodynamics (drug effects, physiology)
• Humans
• Male
• Middle Aged
• Myocardial Infarction (complications, drug therapy, physiopathology)